PDCD1 and rheumatoid arthritis: More recently, PD-1 agonism to treat chronic inflammation has gained traction as a phase 2a trial of a PD-1 agonist antibody for rheumatoid arthritis generated positive results (Gravallese and Thomas, 2023).